Loading…
Incannex Healthcare Inc. is projected to rise to $4.25 by 2027, a +25% move from its current price of $3.39. IXHL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.24 | $3.39 | $3.55 | +0.03% |
| Jul 14 | $3.18 | $3.39 | $3.61 | +0.05% |
| Jul 15 | $3.14 | $3.39 | $3.67 | +0.08% |
| Jul 16 | $3.10 | $3.39 | $3.71 | +0.10% |
| Jul 17 | $3.07 | $3.39 | $3.75 | +0.13% |
| Jul 18 | $3.04 | $3.40 | $3.79 | +0.15% |
| Jul 19 | $3.02 | $3.40 | $3.82 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.02 | $3.40 | $3.82 | +0.18% |
| Week 2 | $2.88 | $3.40 | $4.02 | +0.35% |
| Week 3 | $2.78 | $3.41 | $4.18 | +0.53% |
| Week 4 | $2.70 | $3.41 | $4.32 | +0.71% |
| Week 5 | $2.63 | $3.42 | $4.45 | +0.88% |
| Week 6 | $2.57 | $3.43 | $4.58 | +1.06% |
| Week 7 | $2.51 | $3.43 | $4.69 | +1.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company in the Healthcare sector, headquartered in Sydney, Australia. It engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea, and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc.
is headquartered in Sydney, Australia.
Incannex Healthcare Inc. (IXHL) trades in the Healthcare space and is currently priced at $3.38 with a market capitalization of $40.44M, ranking 4653 by market cap. The current price sits within a broader forecast that envisions modest near-term movement and notable longer-run upside in select years.
The 2026 forecast shows an average price of $3.38, with subsequent years posting rising averages and occasional larger max values.
A major floor 30.3% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 17.7% above — a clean break opens room to run.
A major ceiling 76.1% above — clearing it would confirm fresh momentum.
Key IXHL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IXHL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.57 | Sell | $3.50 | Sell |
| MA 10 | $3.63 | Sell | $3.55 | Sell |
| MA 20 | $3.58 | Sell | $3.56 | Sell |
| MA 50 | $3.73 | Sell | $3.75 | Sell |
| MA 100 | $3.94 | Sell | $4.80 | Sell |
| MA 200 | $7.69 | Sell | $8.84 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.86 | Neutral |
| Stoch RSI (14) | 22.52 | Neutral |
| CCI (20) | -60.72 | Neutral |
| Williams %R (14) | -75.95 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 2.42 | Buy |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 24.05 | Neutral |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 37.96 | Neutral |
| Momentum (10) | 0.19 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 3.34 | Buy |
| ADX (14) | 12.94 | Neutral |
| ATR (14) | 0.14 | Info |
Technically, the 14-day RSI sits at 40, indicating neutral short-term momentum. The stock’s 50-day simple moving average is $3.76 and the 200-day simple moving average is $7.82, suggesting the price could drift toward the longer-term trend over time. Support is identified at $2.92 and resistance at $3.99, framing the near-term bounds.
The 30-day price range spans from $2.47 to $4.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.56 | $3.39 | $4.96 | 0% | Neutral | |
| $3.19 | $4.25 | $6.11 | +25% | Bullish | |
| $2.99 | $4.20 | $6.37 | +24% | Bullish | |
| $2.70 | $3.95 | $6.25 | +16% | Neutral | |
| $2.55 | $3.86 | $6.34 | +14% | Neutral | |
| $2.59 | $4.06 | $6.87 | +20% | Neutral | |
| $2.50 | $4.06 | $7.05 | +20% | Neutral | |
| $3.10 | $5.18 | $9.24 | +53% | Bullish | |
| $3.50 | $6.04 | $11.00 | +78% | Bullish | |
| $3.23 | $5.72 | $10.65 | +69% | Bullish | |
| $3.72 | $7.58 | $15.35 | +124% | Bullish | |
| $5.63 | $12.52 | $28.60 | +269% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.56 | $3.39 | $4.04 | +0.00% |
| August 2026 | $2.72 | $3.26 | $4.06 | -3.75% |
| September 2026 | $2.86 | $3.47 | $4.39 | +6.30% |
| October 2026 | $2.98 | $3.66 | $4.70 | +5.43% |
| November 2026 | $2.94 | $3.64 | $4.74 | -0.52% |
| December 2026 | $3.02 | $3.77 | $4.96 | +3.64% |
Click any year to see its month-by-month IXHL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Incannex Healthcare Inc.'s 2026 outlook centres on $3.39, within a $2.56 to $4.96 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, IXHL could reach as high as $6.11, with a base case around $4.25 and support toward $3.19 — roughly +25% from $3.39. Buyers look set to stay in control over this stretch.
Expect IXHL to range from $2.99 to $6.37 through 2028. The $4.20 average target implies a +24% move from current prices. That is -1% versus the projected 2027 average. Momentum favours further upside here.
The IXHL price prediction for 2029 points to an average of $3.95 (low $2.70, high $6.25) — a potential gain of +16% on today's $3.39. A consolidation phase looks the most probable path here.
In 2030, IXHL is projected to trade between $2.55 and $6.34, averaging $3.86 — a potential gain of +14% from today's $3.39. That is -2% versus the projected 2029 average. Price action looks broadly range-bound.
Incannex Healthcare Inc.'s 2031 outlook centres on $4.06, within a $2.59 to $6.87 range. That is up +5% on the projected 2030 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, IXHL could reach as high as $7.05, with a base case around $4.06 and support toward $2.50 — roughly +20% from $3.39. Price action looks broadly range-bound.
Expect IXHL to range from $3.10 to $9.24 through 2033. The $5.18 average target implies a +53% move from current prices. That is up +28% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The IXHL price prediction for 2034 points to an average of $6.04 (low $3.50, high $11.00) — a potential gain of +78% on today's $3.39. Momentum favours further upside here.
In 2035, IXHL is projected to trade between $3.23 and $10.65, averaging $5.72 — a potential gain of +69% from today's $3.39. That is -5% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Incannex Healthcare Inc.'s 2040 outlook centres on $7.58, within a $3.72 to $15.35 range. That is up +32% on the projected 2035 average. That marks a +124% change versus current levels. Momentum favours further upside here.
By 2050, IXHL could reach as high as $28.60, with a base case around $12.52 and support toward $5.63 — roughly +269% from $3.39. Buyers look set to stay in control over this stretch.
Investing $1,000 in IXHL today (≈ 294.985251 IXHL) could be worth
$3,691.83
+$2,691.83 (+269%) by 2050 · US Dollar
Based on the average projected IXHL price of $12.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IXHLwould be worth at today's price.
$1,000 invested in IXHL on Jul 10, 2025 (≈ 148.148148 IXHL) would be worth
$502.22
-$497.78 (-49.8%) today · 0.50× · US Dollar
Based on a IXHL entry price of $6.75 vs. today's $3.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.97 | $853.9 | -14.6% |
| 1 month ago | $3.91 | $867.01 | -13.3% |
| 3 months ago | $3.12 | $1,086.54 | +8.7% |
| 6 months ago | $11.73 | $289 | -71.1% |
| 1 year ago | $6.75 | $502.22 | -49.8% |
| All time (4.4y) ago | $1,785.6 | $1.9 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IXHL forecast.
Our base-case forecast reaches $6.80 around 2040.
Implied market cap at $6.80: $81.36M
The multi-year forecast paints a mix of neutral to bullish sentiment over time, with notable upside in the later years. The 2026 average is $3.38 (ROI 0%), followed by a bullish tilt in 2027 with an average of $4.33 and ROI 28%, and 2028 with an average of $4.22 and ROI 24.9%. In 2033 the average rises to $4.75 (ROI 40.5%), and 2034 climbs to an average of $5.69 (ROI 68.4%), with 2035 at $5.44 (ROI 61%).
The forecast strengthens further into the 2040s, with 2040 averaging $6.68 (ROI 97.7%) and 2050 averaging $11.38 (ROI 236.8%). The forecast is subject to uncertainty and reflects estimates rather than guarantees. Annualized volatility is high at 90%, underscoring the potential for wide price swings over time.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.81, a possible range from $2.46 to $6.37, and an ROI of 12.7%, with sentiment Neutral.
Forecasts show a mix of neutral and bullish periods, with 2026 neutral and several later years bullish. Peak forecasted ROIs include 68.4% in 2034 and 236.8% in 2050, underscoring potential upside but also uncertainty.
Yes. The 2034 max forecast is $10.61 and the 2035 max is $10.36, with higher max values later such as $13.89 in 2040 and $26.18 in 2050.
The 2050 forecast shows an average price of $11.38, a min of $5.12, a max of $26.18, and a ROI of 236.8%, with sentiment Bullish.
Incannex Healthcare Inc. Community Discussion
0Share your Incannex Healthcare Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.